Emerging Companies

PAQ: small molecules for autophagy-dependent degradation

With a July 15th $30 million series A round led by Sherpa Partners, PAQ joins a growing number of biotechs developing autophagy-dependent degraders that could push targeted degradation beyond protein substrates. ...

Hemab: $55M series A for Novo vets developing bispecific for rare bleeding disorders

Launched by a co-founding team that includes a pair of Novo Nordisk veterans, Hemab is advancing a bispecific antibody the pharma had de-prioritized with the goal of addressing rare bleeding disorders beyond hemophilia. Hemab ApS...

Rivus debuts to find safer way to tap mitochondria for metabolic, CV disorders

With an asset already in the clinic for metabolic disorders, two-year-old Rivus is putting $35 million from a syndicate led by Longitude and Medicxi toward development of small molecules that act in the mitochondrial intermembrane...

Prime Medicine: adding versatility to gene editing

CRISPR-Cas9 gene editing has only started to scratch the surface of its clinical potential, but next-generation iterations including prime editing from new company Prime aren’t far behind. Prime Medicine...

Ji Xing: building a CV pipeline for Chinese patients

With the appointment of longtime Merck veteran Joseph Romanelli as CEO and the close of its $40 million series B, Ji Xing is poised to advance and expand its China-focused cardiovascular pipeline.  Romanelli joins Ji...

Xilis: developing miniature cancer organoids

Duke spinout Xilis emerged from stealth Thursday with a $70 million series A round led by Mubadala Capital to advance a miniature organoid platform designed to guide treatment decisions and accelerate drug development in cancer. ...

Hangzhou Highlightll: Twice the target, hold the tox

Sutent inventor and serial entrepreneur Chris Liang believes Hangzhou Highlightll’s TYK2/JAK1 inhibitor could deliver dual selectivity without the toxicity of a more advanced Pfizer compound against...

OnCusp: Bing Yuan’s newco to provide bridge from innovation to MNC

Former CStone and Merck & Co. dealmaker Bing Yuan and his OnCusp co-founders are using their early stage drug hunting skills to identify cancer assets from the U.S. and China that will appeal...

ArriVent: Bing Yao’s next start-up to test a ‘reverse model’ of cross-border in-licensing strategies

Putting a twist on the cross-border companies that have brought drugs from the West to the Greater China market, newly launched ArriVent is going in the other direction: sourcing innovative products from China and developing...

CellPoint: bringing autologous CAR Ts to point of care

CellPoint is looking to broaden the accessibility and affordability of CAR T therapies with a point-of-care manufacturing platform that enables a one-week turnaround between apheresis and treatment delivery. ...

Abata: engineering targeted Treg cell therapies with TCRs

Launching with a Third Rock Ventures-led $95 million series A round, Abata joins a growing group of companies developing targeted regulatory T cell therapies for autoimmune disorders, starting with progressive multiple sclerosis.  First-generation Treg cell therapies failed...

Lenz: focused on an eye drop for age-related farsightedness

Lenz is well-financed to begin a pivotal study of a pupil-contracting eye drop addressing the largest market in ophthalmology: presbyopia, or age-related farsightedness. Backed by Versant Ventures and RA Capital, newly rechristened Lenz Therapeutics Inc. will...

Mnemo: advancing next-generation cell therapies against epigenetic antigens

Mnemo has raised the largest ever series A round for a French biotech to develop a next-generation CAR T platform and bring its cell therapies into a new target space against epigenetic antigens. Founding investor...

VectorY: Forbion’s next-generation gene therapy play

Forbion-backed VectorY is assembling a set of tools and key personnel to create vectorized antibody therapeutics designed to fill a gap in diseases where other mAbs and gene therapies have fallen short, beginning with ALS. Rather...

Scenic: targeting genetic modifiers to suppress disease drivers

Scenic Biotech is building a compendium of genetic data to identify rare, naturally occurring genetic modifiers that suppress disease pathology despite the presence of disease-causing mutations. Many rare...